Aviti Pharma SAS, founded in 2013, is a biotechnology company focusing on developing innovative medical solutions for topical dermatologic applications.
The company is currently completing pre-clinical testing of a new drug candidate dedicated to the prophylactic treatment of labial and genital herpes (HSV-1 & HSV2).  This drug also targets VZV infections.
Aviti Pharma is committed to providing efficient and reliable solutions to herpesvirida patients, especially those whose condition causes the strongest medical, psychological and social suffering.